Glucagon-like peptide-1 receptor agonists: Exploring the mechanisms from glycemic control to treatment of multisystemic diseases

Figure 1 Glucagon-like peptide-1 receptors are expressed in both cardiomyocytes and endothelial cells, exerting direct and indirect effects on the heart and blood vessels. GLP-1: Glucagon-like peptide-1; GLP-1R: Glucagon-like peptide-1 receptor; LV: Left ventricle; TV: Tricuspid valve.

Figure 2 Glucagon-like peptide-1 receptor agonists improve ovarian dysfunction in a mouse model of polycystic ovary syndrome. GLP-1RA: Glucagon-like peptide-1 receptor agonists; GLP-1: Glucagon-like peptide-1; PCOS: Polycystic ovary syndrome; DFMA: Difluoro methylarginine.

Figure 3 Glucagon-like peptide-1 receptor agonists are extensively involved in various systemic diseases and hold therapeutic potential for a range of conditions. GLP-1R: Glucagon-like peptide-1 receptor; GLP-1: Glucagon-like peptide-1; GI: Gastrointestinal.